Literature DB >> 9169804

Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control.

G Sanguineti1, F B Geara, A S Garden, S L Tucker, K K Ang, W H Morrison, L J Peters.   

Abstract

PURPOSE: This retrospective study was conducted to review the results of treatment and to identify prognostic factors for local and regional control in a population of 378 patients with nasopharyngeal carcinomas treated in a single institution by radiation therapy alone. METHODS AND MATERIAL: All patients were treated at The University of Texas M. D. Anderson Cancer Center between 1954 and 1992 following a consistent treatment philosophy but with evolving technique. There were 286 males and 92 females with a median age of 52 years (range: 16-86 years). The majority of the patients were Caucasian (282 patients, 75%). Thirty-two patients (8%) had one or more cranial nerve deficits. Three-fourths of the patients presented with AJCC Stage IV disease (T4, N0-3, 118 patients; T1-3, N2-3 164 patients). Histologically, 193 tumors (51%) were squamous cell carcinomas, 154 (41%) lymphoepitheliomas, and 31 (8%) unclassified carcinomas. Average total dose varied with T-stage and ranged from 60.2 to 72.0 Gy. Median follow-up time was 10 years.
RESULTS: For the entire population the 5-, 10-, and 20-year actuarial survival rates were 48, 34, and 18%, respectively, with 184 patients (49%) dying of nasopharyngeal cancer. Actuarial control rates at 5, 10, and 20 years were 71, 66, and 66% for the primary site and 84, 83, and 83% for the neck. A total of 100 patients (26%) had local failures and 51 patients (13%) had regional failures with a median time to recurrence of 8.2 months and 13 months, respectively. Advanced T-stage, squamous histology, and presence of cranial nerve deficits were poor prognostic factors for local control in both univariate and multivariate analyses. N-stage and tumor histology were significant factors for neck control. Treatment year, total dose within the ranges used, and duration of treatment did not have any significant effect on local or regional control. The actuarial incidence of Grade 3-5 late complications was 16, 19, and 29% at 5, 10, and 20 years, respectively. Twelve patients (3%) died of treatment-related complications; all but one fatal complication occurred before 1971 and the other in 1976.
CONCLUSIONS: This study shows very good long-term local and regional control rates for nasopharyngeal carcinomas after definitive radiotherapy and establishes a benchmark for newer treatment strategies. Improvements in treatment technique over the years have dramatically reduced the frequency of severe late complications. Patients with advanced stage tumors and differentiated squamous histology have a relatively poor prognosis when treated with conventional radiotherapy and are candidates for dose escalation or combined modality studies.

Entities:  

Mesh:

Year:  1997        PMID: 9169804     DOI: 10.1016/s0360-3016(97)00104-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

1.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part II: Evolving technical choices and toxicity patterns.

Authors:  S M Magrini; S Tonoli; L Costa; N Pasinetti; F Paiar; L Livi; G Simontacchi; I Meattini; L Pegurri; P Borghetti; P Frata; P Ponticelli; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.

Authors:  Evangelia Peponi; Christoph Glanzmann; Guntram Kunz; Christoph Renner; Katja Tomuschat; Gabriela Studer
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

3.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

4.  Radiation-induced lower cranial nerve palsy in patients with head and neck carcinoma.

Authors:  Stefan Janssen; Christoph Glanzmann; Bita Yousefi; Karl Loewenich; Gerhard Huber; Stephan Schmid; Gabriela Studer
Journal:  Mol Clin Oncol       Date:  2015-05-04

5.  Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma.

Authors:  Wendong Zhang; Huiqin Dou; Chileong Lam; Jixi Liu; Jianfeng Zhou; Yunsheng Liu; Xiuwen Wang
Journal:  Tumour Biol       Date:  2013-02-23

6.  Notch1 signaling is activated in cells expressing embryonic stem cell proteins in human primary nasopharyngeal carcinoma.

Authors:  Yue Zhang; Jianhua Peng; Huxiang Zhang; Yi Zhu; Li Wan; Jianfu Chen; Xiaoyun Chen; Renyu Lin; He Li; Xiaoou Mao; Kunlin Jin
Journal:  J Otolaryngol Head Neck Surg       Date:  2010-04

7.  Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.

Authors:  Yanjie You; Wenjun Yang; Zhizhong Wang; Huimin Zhu; Haijun Li; Canfeng Lin; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2013-06-06       Impact factor: 6.730

8.  ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.

Authors:  Yanjie You; Wenjun Yang; Xin Qin; Fei Wang; Haijun Li; Canfeng Lin; Wenmei Li; Cunguo Gu; Yinpo Zhang; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2015-02-24       Impact factor: 6.730

9.  Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.

Authors:  Shaojun Lin; Jiade Jay Lu; Lu Han; Qisong Chen; Jianji Pan
Journal:  BMC Cancer       Date:  2010-02-10       Impact factor: 4.430

Review 10.  Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.

Authors:  Anne W M Lee
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.